Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.

Name: Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study.
Author: Agius, Mark A

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study. — المؤلف: Agius, Mark A — Multiple sclerosis (Houndmills, Basingstoke,

المؤلف: Agius, Mark A
النشر: Multiple sclerosis (Houndmills, Basingstoke, England) 20191213
الوصف: 235-245 p.
الموضوعات: Adult؛ Antibodies, Monoclonal, Humanized؛ Dose-Response Relationship, Drug؛ Female؛ Humans؛ Male؛ Middle Aged؛ Multiple Sclerosis, Relapsing-Remitting